Assignee
VIVUS INC
US·38 granted patents·55 pending applications·2,333 citations·filing 1993–2021
Top patents by PatentIndex Score
93 records- 0199US7226910B2Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonistsVIVUS INC·Filed 2005·Granted Jun 5, 2007·103 cites·23 claims
- 0297US6472434B1Method for minimizing excess collagen depositionVIVUS INC·Filed 2000·Granted Oct 29, 2002·110 cites·32 claims
- 0397US6469016B1Treatment of female sexual dysfunction using phosphodiesterase inhibitorsVIVUS INC·Filed 2000·Granted Oct 22, 2002·148 cites·64 claims
- 0497US6037346ALocal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunctionVIVUS INC·Filed 1998·Granted Mar 14, 2000·224 cites·94 claims
- 0597US5877216ATreatment of female sexual dysfunctionVIVUS INC·Filed 1997·Granted Mar 2, 1999·333 cites·25 claims
- 0696US6593313B2Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunctionVIVUS INC·Filed 2001·Granted Jul 15, 2003·72 cites·69 claims
- 0796US6495154B1On demand administration of clomipramine and salts thereof to treat premature ejaculationVIVUS INC·Filed 2000·Granted Dec 17, 2002·104 cites·71 claims
- 0895US7553818B2Combination therapy for effecting weight loss and treating obesityVIVUS INC·Filed 2006·Granted Jun 30, 2009·23 cites·24 claims
- 0995US6403597B1Administration of phosphodiesterase inhibitors for the treatment of premature ejaculationVIVUS INC·Filed 2001·Granted Jun 11, 2002·166 cites·94 claims
- 1094US7674776B2Combination therapy for effecting weight loss and treating obesityVIVUS INC·Filed 2006·Granted Mar 9, 2010·28 cites·59 claims
- 1194US7659256B2Combination therapy for effecting weight loss and treating obesityVIVUS INC·Filed 2006·Granted Feb 9, 2010·22 cites·29 claims
- 1294US6127363ALocal administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunctionVIVUS INC·Filed 1999·Granted Oct 3, 2000·136 cites·106 claims
- 1392US7056890B2Combination therapy for effecting weight loss and treating obesityVIVUS INC·Filed 2003·Granted Jun 6, 2006·47 cites·54 claims
- 1492US6156753ALocal administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunctionVIVUS INC·Filed 1999·Granted Dec 5, 2000·113 cites·67 claims
- 1592US5474535ADosage and inserter for treatment of erectile dysfunctionVIVUS INC·Filed 1993·Granted Dec 12, 1995·92 cites·21 claims
- 1691US8895058B2Low dose topiramate/phentermine composition and methods of use thereofVIVUS INC·Filed 2013·Granted Nov 25, 2014·9 cites·32 claims
- 1791US5922341ALocal administration of pharmacologically active agents to treat premature ejaculationVIVUS INC·Filed 1997·Granted Jul 13, 1999·102 cites·80 claims
- 1890US8895057B2Escalating dosing regimen for effecting weight loss and treating obesityVIVUS INC·Filed 2013·Granted Nov 25, 2014·8 cites·33 claims
- 1989US9011905B2Low dose topiramate/phentermine composition and methods of use thereofVIVUS INC·Filed 2014·Granted Apr 21, 2015·6 cites·38 claims
- 2088US6593369B2Methods, compositions, and kits for enhancing female sexual desire and responsivenessVIVUS INC·Filed 2001·Granted Jul 15, 2003·23 cites·15 claims
- 2187US9011906B2Escalating dosing regimen for effecting weight loss and treating obesityVIVUS INC·Filed 2014·Granted Apr 21, 2015·5 cites·31 claims
- 2287US6946141B2As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculationVIVUS INC·Filed 2001·Granted Sep 20, 2005·24 cites·68 claims
- 2387US6548490B1Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunctionVIVUS INC·Filed 1999·Granted Apr 15, 2003·54 cites·51 claims
- 2487US6228864B1Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculationVIVUS INC·Filed 1998·Granted May 8, 2001·68 cites·18 claims
- 2585US10058532B2Methods of preventing progression to type 2 diabetes mellitusVIVUS INC·Filed 2017·Granted Aug 28, 2018·3 cites·16 claims
- 2683US9724327B2Methods of preventing progression to type 2 diabetes mellitusVIVUS INC·Filed 2014·Granted Aug 8, 2017·4 cites·17 claims
- 2781US10028916B2Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and useVIVUS INC·Filed 2015·Granted Jul 24, 2018·3 cites·13 claims
- 2875US5820587AMethod and kit for preventing erectile dysfunctionVIVUS INC·Filed 1997·Granted Oct 13, 1998·37 cites·59 claims
- 2973US2020188352A1Escalating dosing regimen for effecting weight loss and treating obesityVIVUS INC·Filed 2020·Application pending·0 cites
- 3073US2020188313A1Low dose topiramate/phentermine composition and methods of use thereofVIVUS INC·Filed 2020·Application pending·0 cites
- 3172US2021161932A1Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonistVIVUS INC·Filed 2021·Application pending·0 cites
- 3271US2020129474A1Combination therapy for effecting weight loss and treating obesityVIVUS INC·Filed 2020·Application pending·0 cites
- 3371US2019350866A1Low dose topiramate/phentermine composition and methods of use thereofVIVUS INC·Filed 2018·Application pending·0 cites
- 3470US2019350897A1Escalating dosing regimen for effecting weight loss and treating obesityVIVUS INC·Filed 2018·Application pending·0 cites
- 3569US5925629ATransurethral administration of androgenic agents for the treatment of erectile dysfunctionVIVUS INC·Filed 1997·Granted Jul 20, 1999·32 cites·26 claims
- 3669US5773020ATreatment of erectile dysfunctionVIVUS INC·Filed 1997·Granted Jun 30, 1998·72 cites·18 claims
- 3768US2021283096A1Methods of treating obesity in responder and non-responder populationsVIVUS INC·Filed 2021·Application pending·0 cites
- 3867US2020135318A1Methods of regulating access to qsymia to mitigate potential drug-associated risksVIVUS INC·Filed 2020·Application pending·0 cites
- 3967US2021338642A1Compositions and methods for the treatment or prevention of pulmonary hypertensionVIVUS INC·Filed 2021·Application pending·0 cites
- 4067US2020030239A1Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and useVIVUS INC·Filed 2019·Application pending·0 cites
- 4167US2019350864A1Pharmaceutical formulationsVIVUS INC·Filed 2018·Application pending·0 cites
- 4267US2019139635A1Methods of regulating access to qsymia to mitigate potential drug-associated risksVIVUS INC·Filed 2018·Application pending·0 cites
- 4367US2014288944A1Methods of regulating access to qsymia to mitigate potential drug-associated risksVIVUS INC·Filed 2014·Application pending·0 cites
- 4466US2020069658A1Combination therapy for pulmonary hypertensionVIVUS INC·Filed 2019·Application pending·0 cites
- 4566US2021267951A1Combination therapy for pulmonary hypertensionVIVUS INC·Filed 2021·Application pending·0 cites
- 4666US2014294950A1Methods of treating obesity in responder and non-responder populationsVIVUS INC·Filed 2014·Application pending·0 cites
- 4766US2019167633A1Combination therapy for effecting weight loss and treating obesityVIVUS INC·Filed 2018·Application pending·0 cites
- 4866US2015025134A1Compositions and Methods for the Treatment of Sleep ApneaVIVUS INC·Filed 2014·Application pending·0 cites
- 4965US2019142786A1Methods of treating obesity in responder and non-responder populationsVIVUS INC·Filed 2018·Application pending·0 cites
- 5065US2014308346A1Combination therapy for effecting weight loss and treating obesityVIVUS INC·Filed 2014·Application pending·0 cites
Showing the top 50 of 93 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when VIVUS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →